S
Stephen F. Little
Researcher at United States Army Medical Research Institute of Infectious Diseases
Publications - 60
Citations - 4508
Stephen F. Little is an academic researcher from United States Army Medical Research Institute of Infectious Diseases. The author has contributed to research in topics: Bacillus anthracis & Anthrax vaccines. The author has an hindex of 37, co-authored 60 publications receiving 4411 citations. Previous affiliations of Stephen F. Little include United States Department of the Army.
Papers
More filters
Journal ArticleDOI
In vitro correlate of immunity in a rabbit model of inhalational anthrax.
Margaret L. Pitt,Stephen F. Little,Bruce E. Ivins,P.F. Fellows,J. Barth,John Hewetson,Paul H. Gibbs,Mark T. Dertzbaugh,Arthur M. Friedlander +8 more
TL;DR: A serological correlate of vaccine-induced immunity was identified in the rabbit model of inhalational anthrax and antibody levels to PA at both 6 and 10 weeks were significant predictors of survival.
Journal ArticleDOI
Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.
Bruce E. Ivins,Margaret L. Pitt,P.F. Fellows,Joseph Farchaus,G. E. Benner,David M. Waag,Stephen F. Little,G.W. Anderson,Paul H. Gibbs,Arthur M. Friedlander +9 more
TL;DR: The authors examined the efficacy of Bacillus anthracis protective antigen (PA) combined with adjuvants as vaccines against an aerosol challenge of virulent anthrax spores in rhesus macaques.
Journal ArticleDOI
The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores
TL;DR: The anti-PA Ab-specific immunity induced by AVA has anti-spore activity and might have a role in impeding the early stages of infection with B. anthracis spores.
Journal ArticleDOI
Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.
TL;DR: It is demonstrated that antibodies produced against only PA can provide passive protection against anthrax infection in guinea pigs.
Journal ArticleDOI
Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig.
TL;DR: It is concluded that antibodies to toxin components may not be sufficient to provide protection against all strains of B. anthracis and that other antigens may play a role in active immunity and that the efficacy of anthrax vaccines must be tested by using vaccine-resistant isolates ifprotection against all possible challenge strains is to be assured.